Therapeutic potential of nanocarrier for overcoming to P-glycoprotein

Journal of Drug Targeting

Volumn 22, Issue 10, 2014, Pages 859-870

  Kaur, Vimratjeet ^a   Garg, Tarun ^a   Rath, Goutam ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Cancer targeting; Drug targeting; P glycoprotein; P gp inhibition

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOSPORIN A; DENDRIMER; DIGOXIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EXCIPIENT; GLYCOPROTEIN P INHIBITOR; LIPOSOME; MICROSPHERE; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; PACLITAXEL; SAQUINAVIR; SOLID LIPID NANOPARTICLE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; NANOPARTICLE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; HUMAN; HYBRID; HYDROGEL; MICELLE; MICROEMULSION; NANOENCAPSULATION; NONHUMAN; PROTEIN STRUCTURE; PROTEIN TARGETING; THERAPY; THERAPY EFFECT; ANIMAL; BIOAVAILABILITY; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; P-GLYCOPROTEIN;

EID: 84910104897     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.947295     Document Type: Article

References (101)

1. Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an updated review. Int J Pharm Invest 2012;2:2-11.
2. Yamaguchi H, Yano I, Saito H, Inui K-I. Pharmacokinetic role of Pglycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 2002;300:1063-9.
3. Frezard F, Pereira-Maia E, Quidu P, et al. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur J Biochem 2001;268:1561-7.
4. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48:347-59.
5. Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002; 91:1991-2002.
6. Huang I-P, Sun S-P, Cheng S-H, et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol Cancer Ther 2011;10:761-9.
7. Huwyler J, Cerletti A, Fricker G, et al. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002;10:73-9.
8. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003; 11:391-406.
9. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
10. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1. Annu Rev Pharmacol Toxicol 1999;39:361-98.
11. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011;50:161-78.
12. Edwards JE, Alcorn J, Savolainen J, et al. Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier. Antimicrob Agents Chemother 2005;49: 1626-8.
13. Melaine N, Liénard M-O, Dorval I, et al. Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biol Reprod 2002;67:1699-707.
14. Sauna ZE, Smith MM, Müller M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001;33:481-91.
15. Goren D, Horowitz AT, Tzemach D, et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6: 1949-57.
16. Beaulieu E, Demeule M, Ghitescu L, Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997;326:539-44.
17. Sharom FJ, Liu R, Qu Q, Romsicki Y. Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol 2001;12:257-65.
18. Srivalli KMR, Lakshmi P. Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharm Sci 2012;48:353-67.
19. Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009;12:46-78.
20. Bansal T, Akhtar N, Jaggi M, et al. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009;14:1067-74.
21. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 2010; 5:597-615.
22. Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003;46:4805-17.
23. Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterationsin membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995;228:1020-9.
24. Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 2007;13:3276-85.
25. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and the dance macabre between humans and bacteria. Nat Rev Drug Discov 2007;6:56-65.
26. Kerr D, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-42.
27. Bates S, Kang M, Meadows B, et al. A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar). Cancer 2001;92:1577-90.
28. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7: 861-79.
29. Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv 2014. [Epub ahead of print]. doi:10.3109/10717544.2013.879355.
30. Lo Y-L. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release 2003;90:37-48.
31. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005;25:445-53.
32. Liu C, Wu J, Shi B, et al. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm 2006;32:115-23.
33. Carreno-Gomez B, Duncan R. Compositions with enhanced oral bioavailability. Google Patents, 2001.
34. Carreno-Gomez B, Duncan R. Compositions with enhanced oral bioavailability. US Patent 20,030,211,072, 2003.
35. Föger F, Kafedjiiski K, Hoyer H, et al. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J Drug Target 2007;15:132-9.
36. Shen Q, Lin Y, Handa T, et al. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 2006;313:49-56.
37. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002;4:193-205.
38. Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci 2007;10:319-31.
39. Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119-31.
40. Mahmoudzadeh M, Fassihi A, Emami J, et al. Physicochemical, pharmaceutical and biological approaches toward designing optimized and efficient hydrophobically modified chitosan-based polymeric micelles as a nanocarrier system for targeted delivery of anticancer drugs. J Drug Target 2013;21:693-709.
41. Moutinho CG, Matos CM, Teixeira JA, Balcao VM. Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: state-of-the-art. J Drug Target 2012;20:114-41.
42. Niu J, Huang A, Xiao Y, et al. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the selfassembly supramolecular nanocarrier. J Drug Target 2013;21: 415-26.
43. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92.
44. Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009;37:300-5.
45. Chen Y, Zheng X-L, Fang D-L, et al. Dual Agent Loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model. Int J Mol Sci 2014;15:2761-72.
46. Emilienne Soma C, Dubernet C, Bentolila D, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000;21:1-7.
47. Chavanpatil MD, Khdair A, Gerard B, et al. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm 2007;4:730-8.
48. Kopeček J, Kopečková P, Minko T, Lu Z-R. HPMA copolymer- anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000;50:61-81.
49. Nori A, Kopeček J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005;57:609-36.
50. Omelyanenko V, Kopečková P, Gentry C, Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release 1998;53:25-37.
51. Schmitz T, Hombach J, Bernkop-Schnürch A. Chitosan-N-acetyl cysteine conjugates: in vitro evaluation of permeation enhancing and P-glycoprotein inhibiting properties. Drug Deliv 2008;15: 245-52.
52. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed 2009; 48:5418-29.
53. Jones M-C, Leroux J-C. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48:101-11.
54. Mourya V, Inamdar N, Nawale R, Kulthe S. Polymeric micelles: general considerations and their applications. Indian J Pharm Educ Res 2011;45:128-38.
55. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv 2013;2013:Article ID 340315, 15 pages.
56. Yao H-J, Ju R-J, Wang X-X, et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011;32:3285-302.
57. Wei Z, Yuan S, Hao J, Fang X. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. Eur J Pharm Biopharm 2013;83:266-74.
58. Zhang Z, Lee SH, Gan CW, Feng S-S. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 2008;25: 1925-35.
59. Cambon A, Rey-Rico A, Barbosa S, et al. Poly (styrene oxide)-poly (ethylene oxide) block copolymers: from ''classical'' chemotherapeutic nanocarriers to active cell-response inducers. J Control Release 2013;167:68-75.
60. Duan X, Xiao J, Yin Q, et al. Smart pH-sensitive and temporalcontrolled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013;7:5858-69.
61. Alagusundaram M, Umashankari K, Badarinath AV, et al. Microspheres as a novel drug delivery sysytem - a review. Int J ChemTech Res 2009;1:526-34.
62. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst 2012;29: 1-63.
63. Derakhshandeh K, Hosseinalizadeh A, Nikmohammadi M. The effects of PLGA microparticles on intestinal absorption of pglycoprotein substrate using the everted rat intestinal sac model. Arch Pharmacol Res 2011;34:1989-97.
64. Liu Z, Bendayan R, Wu XY. Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance. J Pharm Pharmacol 2001;53:779-87.
65. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst 2013;30:369-409.
66. Št'astný M, Plocová D, Etrych T, et al. HPMA-hydrogels containing cytostatic drugs: kinetics of the drug release and in vivo efficacy. J Control Release 2002;81:101-11.
67. Št'astný M, Strohalm J, Plocova D, et al. A Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibodytargeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur J Cancer 1999;35:459-66.
68. Garg T, Goyal AK. Biomaterial-based scaffolds - current status and future directions. Expert Opin Drug Deliv 2014;11:767-89.
69. Mooberry LK, Nair M, Paranjape S, et al. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 2010;18:53-8.
70. Bromberg L, Alakhov V. Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 2003;88: 11-22.
71. Patelx H, Patel P. Dendrimer applications - a review. Int J Pharm BioSci 2013;4:454-63.
72. Sukumar UK, Bhushan B, Dubey P, et al. Emerging applications of nanoparticles for lung cancer diagnosis and therapy. Int Nano Lett 2013;3:1-17.
73. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 2004;95:447-53.
74. Daming C, Qiwu X, Shixin G, et al. PAMAM-drug complex for delivering anticancer drug across blood-brain barrier in-vitro and in-vivo. Afr J Pharm Pharmacol 2009;3:227-33.
75. Najlah M, Freeman S, Attwood D, D'Emanuele A. Synthesis and assessment of first-generation polyamidoamine dendrimer prodrugs to enhance the cellular permeability of P-gp substrates. Bioconjug Chem 2007;18:937-46.
76. Teow HM. An investigation of the use of dendrimer-based carrier to cross cellular barriers. Preston, Lancashire, England: University of Central Lancashire; 2010.
77. Zhou Y, Ning Q, Yu DN, et al. Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system. J Pharm Pharmacol 2014;66:903-11.
78. Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011;8:683-700.
79. Barthelemy P, Laforet J, Farah N, Joachim J. Compritol® 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm 1999;47:87-90.
80. Baviskar D, Amritkar A, Chaudhari H, Jain D. Modulation of drug release from nanocarriers loaded with a poorly water soluble drug (flurbiprofen) comprising natural waxes. Die Pharmazie - Int J Pharm Sci 2012;67:701-5.
81. Muèller RH, Maèder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
82. Dharmala K, Yoo JW, Lee CH. Development of Chitosan-SLN Microparticles for chemotherapy: in vitro approach through effluxtransporter modulation. J Control Release 2008;131:190-7.
83. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004;93:1993-2008.
84. Yin Y-M, Cui F-D, Mu C-F, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009;140:86-94.
85. Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci 2013;102:1343-54.
86. Nornoo AO, Zheng H, Lopes LB, et al. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm 2009;71:310-17.
87. Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 2013;85:427-43.
88. de Verdiere AC, Dubernet C, Nemati F, et al. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother Pharmacol 1994;33:504-8.
89. Wong HL, Bendayan R, Rauth AM, et al. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006;317:1372-81.
90. Lamprecht A, Benoit J-P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous Pglycoprotein inhibition. J Control Release 2006;112:208-13.
91. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006;116:275-84.
92. Shuhendler AJ, Cheung RY, Manias J, et al. A novel doxorubicinmitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2010;119:255-69.
93. Wan C, Letchford K, Jackson JK, Burt HM. The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance. Int J Nanomed 2012;8:379-91.
94. Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 2009;9:399.
95. Ling G, Zhang P, Zhang W, et al. Development of novel selfassembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010;148:241-8.
96. Xu L, Li H, Wang Y, et al. Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors. Oncol Lett 2014;7: 387-92.
97. Lu H-L, Syu W-J, Nishiyama N, et al. Dendrimer phthalocyanineencapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo. J Control Release 2011;155: 458-64.
98. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136: 21-9.
99. Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010;31:358-65.
100. Meng H, Liong M, Xia T, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010;4:4539-50.
101. Minko T, Kopečková P, Pozharov V, Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 1998;54: 223-33.